Glucose Tolerance and Body Mass Index in Achondroplastic Children Receiving HGH Therapy.
|
Accession number;02A0168949
|
| Title;Glucose Tolerance and Body Mass Index in Achondroplastic Children Receiving HGH Therapy. |
| Author;
MIYAZAWA MARI
(Okayama Univ., Sch. of Med.)
|
Journal Title;Journal of the Japan Pediatric Society
|
Journal Code:F0896A
|
ISSN:0001-6543
|
|
VOL.106;NO.1;PAGE.46-51(2002)
|
| Figure&Table&Reference;FIG.1, TBL.3, REF.13 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;Aim: Patients with achondroplasia have been treated with human growth hormone (hGH) to improve their short stature. Achondroplastic patients look overweight, but there is no consensus about obesity in those patients. Sometimes patients with other diseases show impaired glucose tolerance when they are treated with hGH. Therefore, it is necessary to make a standard for obesity and to assess risk factor on impaired glucose tolerance in achondroplasia. To clarify the risk factors in achondroplasia, we studied glucose tolerance and body mass index (BMI) in achondroplastic children receiving hGH therapy retrospectively. Method: Thirty-one achondroplastic children were studied, who had been treated more than four years. Anthropometirc measurements were performed ever three months during therapy. Oral glucose tolerance test (OGTT) was performed ever two years during therapy. Results: Six patients showed impaired glucose tolerance in OGTT. Using logistic regression analysis, risk factors for the impaired glucose tolerance were as follow; BMI.GEQ.23 during therapy, treatment started late, expression of the pubertal signs during GH. Conclusion: It is important to monitor the BMI and pubertal development in achondroplastic patients in hGH therapy, especially those who started treatment late. (author abst.) |
|
|
|
Related Articles;
|
|
